Autoimmune biologic therapy
2 conceptsEnbrel is Amgen's etanercept biologic for inflammatory autoimmune conditions, including rheumatoid arthritis and related diseases.
A tighter look at the products that matter most to Amgen, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 4 structured disruption concepts across the current product set.
Autoimmune biologic therapy
2 conceptsEnbrel is Amgen's etanercept biologic for inflammatory autoimmune conditions, including rheumatoid arthritis and related diseases.
Cardiovascular biologic therapy
2 conceptsRepatha is Amgen's evolocumab PCSK9 inhibitor used to reduce LDL-C and reduce cardiovascular event risk in indicated patients.
Paper trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Amgen · annual report
Primary source for 2025 revenue, net income, product sales, product descriptions, and management discussion of Enbrel and Repatha trends.
Reviewed 2026-05-25
Amgen · product page
Official product directory confirming Enbrel and Repatha product pages and Amgen's marketed therapeutics footprint.
Reviewed 2026-05-25
StockAnalysis · market data
Market-data source for Amgen's current market capitalization and ranking context as of May 2026.
Reviewed 2026-05-25
U.S. Food and Drug Administration · regulatory filing
Regulatory source explaining biosimilars, interchangeability, lower-cost potential, and FDA's role in therapeutic substitution.
Reviewed 2026-05-25
Open Insulin · open source project
Open-source biologics manufacturing reference for small-scale production, open techniques, organisms, protocols, and open hardware concepts.
Reviewed 2026-05-25
Open Targets · open source project
Open-source therapeutic target identification platform relevant to decentralized drug-discovery infrastructure.
Reviewed 2026-05-27